anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

214,201-214,260 of 319,975

filter-aware
19
Invitae | Results Presentation Deck | 28 slidesInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
20
Invitae | Results Presentation Deck | 28 slidesInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
21
Includes pro forma adjustments for exited businesses and geographies.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
22
Pro forma figures exclude exited businesses and geographies.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
23
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
24
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
25
The table details specific line items like impairment, restructuring costs, and stock-based compensation adjustments.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
26
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
27
The table reconciles net cash flow changes to cash burn, including adjustments for investments and debt issuance.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
28
Invitae | Results Presentation Deck | 28 slidesInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
01
Slide 1
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Attention1 hit
02
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Interest1 hit
03
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Interest1 hit
04
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
05
The slide uses a causal-chain/before-after-bridge hybrid structure to link specific problems to specific solutions.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
06
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · WhyLoop · Cost Of Inaction1 hit
07
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Need1 hit
08
The slide uses bar charts to compare ASMs and Revenue growth guidance for Q2 and Q3.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
09
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
10
The slide uses a bar chart to show CASM ex-Fuel performance vs guidance, with specific callouts for operational headwinds.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
11
The slide uses a bar chart to highlight JetBlue's position relative to competitors, with specific focus on liquidity and fuel hedging.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
12
Includes footnotes regarding pilot union agreement, fuel hedging, and engine removal requirements.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
13
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
14
Includes detailed breakdown of adjustments for fuel, non-airline expenses, and special items.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
15
Standard financial disclosure slide for JetBlue Airways.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
16
This is a continuation slide for a financial reconciliation table.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
17
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
18
Data as of July 31, 2023.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations 1 hit
19
jetBlue | Results Presentation Deck | 19 slidesjetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Beat · Satisfaction1 hit
01
Slide 1
Includes company logo, tagline, and date.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
02
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a split-layout with company identity on the left and a list of achievements on the right.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
04
TPD = Targeted Protein Degradation. The slide uses a four-column layout to structure the company's value proposition.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
05
TPD stands for Targeted Protein Degradation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
06
The slide uses a dot-matrix representation to indicate therapeutic focus areas for specific drug candidates.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
07
The slide uses a Gantt-chart style layout to show the progression of various drug programs.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
08
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
09
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
11
The slide uses a combination of a biological mechanism diagram, a market data table, and a callout box for competitive limitations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
12
The slide uses a side-by-side comparison framework to contrast healthy volunteer data with patient data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
14
Clinical trial baseline data table.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
20
The slide displays 12 individual bar charts (4 for AD, 8 for HS) representing gene expression changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
23
Includes before/after photography, clinical efficacy table, and biomarker reduction charts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
25
Data presented for All HS Patients (N=12) and Moderate to Severe (N=10) subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
28
Includes patient profile, clinical efficacy table, before/after photos, and a bar chart of biomarker reduction.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
29
Includes before/after clinical photos and a longitudinal biomarker chart.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
30
The slide uses a comparison table to highlight superior efficacy metrics for the drug candidate.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
31
The footer highlights the safety profile: no serious adverse events (SAEs), no drug-related infections, and no dose interruptions or discontinuations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit